CorMedix Inc
Slēgts
SektorsVeselības aprūpe
8.72 -2.13
Pārskats
Akcijas cenas izmaiņa
24h
Min
8.71
Max
8.81
Ienākumi | 25M 39M |
|---|---|
Pārdošana | -1.2M 127M |
P/E Sektora vidējais | 3.936 49.052 |
EPS | 0.35 |
Peļņas marža | 30.293 |
Darbinieki | 191 |
EBITDA | 7.7M 74M |
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +63.04% upside |
Nākamie ieņēmumi | 2026. g. 6. aug. |
|---|
Tirgus kapitalizācija | 69M 670M |
|---|---|
Iepriekšējā atvēršanas cena | 10.85 |
Iepriekšējā slēgšanas cena | 8.72 |
Ziņu noskaņojums
By Acuity
67%
33%
302 / 342 Rangs Healthcare
CorMedix Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
